|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Associating liver partition and portal vein ligation for staged hepatectomy: From technical evolution to oncological benefit显示文摘Associating liver partition and portal vein ligation for staged hepatectomy(ALPPS) is a novel approach in liver surgery that allows for extensive resection of liver parenchyma by inducing a rapid hypertrophy of the future remnant liver. However,recent reports indicate that not all patients eligible for ALPPS will benefit from this procedure. Therefore,careful patient selection will be necessary to fully exploit possible benefits of ALPPS. Here,we provide a comprehensive overview of the technical evolution of ALPPS with a special emphasis on safety and oncologic efficacy. Furthermore,we review the contemporary literature regarding indication and benefits,but also limitations of ALPPS. | Jun Li Florian Ewald Amit Gulati Bjon Nashan | 2016 | World Journal of Gastrointestinal Surgery2016，8，2： | 9 |
| 2 | Factors associated with long-term survival after liver transplantation:A retrospective cohort study显示文摘AIM To identify predictive factors associated with long-term patient and graft survival(> 15 years) in liver transplant recipients.METHODS Medical charts of all de novo adult liver transplant recipients(n = 140) who were transplanted in Hamburg between 1997 and 1999 were retrospectively reviewed.In total,155 transplantations were identified in this time period(15 re-transplantations).Twenty-six orthotopic liver transplant(OLT) recipients were early lost to followup due to moving to other places within 1 year after transplantation.All remaining 114 patients were included in the analysis.The following recipient factors were analysed:Age,sex,underlying liver disease,pre-OLT body mass index(BMI),and levels of alanine aminotransferase(ALT),bilirubin,creatinine and gammaglutamyltransferase(gamma-GT),as well as warm and cold ischemia times.Furthermore,the following donor factors were assessed:Age,BMI,cold ischemia time and warm ischemia time.All surviving patients were followed until December 2014.We divided patients into groups according to their underlying diagnosis:(1) hepatocellularcarcinoma(n = 5,4%);(2) alcohol toxic liver disease(n = 25,22.0%);(3) primary sclerosing cholangitis(n = 6,5%);(4) autoimmune liver diseases(n = 7,6%);(5) hepatitis C virus cirrhosis(n = 15,13%);(6) hepatitis B virus cirrhosis(n = 21,19%);and(7) other(n = 35,31%).The group 'other' included rare diagnoses,such as acute liver failure,unknown liver failure,stenosis and thrombosis of the arteria hepatica,polycystic liver disease,Morbus Osler and Caroli disease.RESULTS The majority of patients were male(n = 70,61%).Age and BMI at the time point of transplantation ranged from 16 years to 69 years(median:53 years) and from 15 kg/m^2 to 33 kg/m^2(median:24),respectively.Sixty-six OLT recipients(58%) experienced a follow-up of 15 years after transplantation.Recipient's age(P = 0.009) and BMI(P = 0.029) were identified as risk factors for death by χ~2-test.Kaplan-Meier analysis confirmed BMI or age above the median as predictors of decreased long-term survival(P = 0.008 and P = 0.020).Hepatitis B as underlying disease showed a trend for improved long-term survival(P = 0.049,χ~2-test,P = 0.055;Kaplan-Meier analysis,Log rank).Pre-transplant bilirubin,creatinine,ALT and gamma-GT levels were not associated with survival in these patients of the pre-era of the model of end stage liver disease.CONCLUSION The recipients' age and BMI were predictors of longterm survival after OLT,as well as hepatitis B as underlying disease.In contrast,donors' age and BMI were not associated with decreased survival.These findings indicate that recipient factors especially have a high impact on long-term outcome after liver transplantation. | Sven Pischke Marie C Lege Moritz von Wulffen Antonio Galante Benjamin Otto Malte H Wehmeyer Uta Herden Lutz Fischer Bjorn Nashan Ansgar W Lohse Martina Sterneck | 2017 | World Journal of Hepatology2017，9，8： | 5 |
| 3 | Presence of EpCAM‐positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma显示文摘 | Kornelius Schulze Christin Gasch Katharina Staufer Bj?rn Nashan Ansgar W. Lohse Klaus Pantel Sabine Riethdorf Henning Wege | 2013 | Cancer2013，，9： | 2 |
| 4 | Wound Healing Complications and the Use of Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation: A Critical Review of the Literature显示文摘 | Bj?rn Nashan Franco Citterio | 2012 | Transplantation Journal2012，，6： | 1 |
| 5 | Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: Immediate switch to adefovir dipivoxil appears to be indicated 显示文摘 | Wiegand J Tischendorf J J Nashan B | 2004 | Z Gastroenterol2004，42，1： | 1 |
| 6 | The role of mTOR in- hibitors in liver transplantation: reviewing the evidence 显示文摘 | Klintmalm GB Nashan B | 2014 | J Transplant2014，2014，84： | 1 |
| 7 | Clinical and subclinical acute rejection ear ly after liver transplantation: contributing factors and relevance for the long-term course显示文摘 | Tippner C Nashan B Hoshino K Schmidt-Sandte E Akimaru K B/Sker K H | 2001 | Transplantation2001，72，： | 1 |
| 8 | Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients显示文摘 | Nashan B Luck R Kliem V | 2000 | Transplantation2000，70，8： | 1 |
| 9 | Reduction of acute renal allograft rejection by daclizumab显示文摘 | Nashan B Light I Hardie I | 1999 | Transplantation1999，67，： | 1 |
| 10 | Reduction of acute renal allograft rejection by daclizumab :daclizumab double therapy study group显示文摘 | Nashan B Light S Hardie IR | 1999 | Transplantation1999，67，： | 1 |
| 11 | Pharmacokinetics,efficacy,and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver trans-plant recipients显示文摘 | Nashan B Saliba F Durand F | 2009 | Liver Transpl2009，15，2： | 1 |
| 12 | Clinical and subclinical acute rejection early after liver transplantation:contributing factors and relevance for the long-term course显示文摘 | Tippner C Nashan B Hoshino K Schmidt-Sandte E Akimaru K B(o)ker K H | 2001 | Transplantation2001，72，： | 1 |
| 13 | A prospective study on living related kidney donors' quality of life in the first year: choosing appropriate reference data 显示文摘 | Kroencke S Fischer L Nashan B | 2012 | Clinical Transplan- tation2012，26，4： | 1 |
| 14 | Outcome of 22 successsful pregnancies after liver transplantation显示文摘 | Wu A Nashan B Messner U | 1998 | Clin Transplant1998，12，5： | 1 |
| 15 | Fibrosis in chronic rejection of human liver allografts: expression patterns of transforming growth factor TGF beta 1 and TGF beta 3显示文摘 | DEMICI G NASHAN B PICHLMAYR R | 1996 | Transplantation1996，62，2： | 1 |
| 16 | Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated显示文摘 | Wiegand J Tischendorf JJ Nashan B | 2004 | Z Gastroenterol2004，42，1： | 1 |
| 17 | 3D CT modeling of hepatic vessel architecture and volume calculations in living donated liver transplantation显示文摘 | Frericks BB Caldorone FC Nashan B | 2004 | Eur Radiol2004，14，： | 1 |
| 18 | Renal allograft allocation for children: are we penalizing children to not penalize adults 显示文摘 | Nashan B | 2004 | Transplantation2004，77，8： | 1 |
| 19 | Cyclospofine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study 显示文摘 | Ekberg H Grinyo J Nashan B | 2007 | Am J Transplant2007，7，3： | 1 |
| 20 | Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens:a comparative review显示文摘 | Nashan B | 2005 | BioDrugs2005，19，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员